VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) plans as previously announced to release its report on results for the third quarter 2018 on Monday, October 29 shortly after 21:00 Central European Time (CET) / 16:00 Eastern Daylight Time (EDT). A conference call is planned for Tuesday, October 30 at 14:00 CET / 9:00 EDT hosted by Peer M. Schatz, Chief Executive Officer, and Roland Sackers, Chief Financial Officer. (For Europe: Due to the U.S. time switch, our Q3 report (21:00 instead of 22:00) and investor conference call (14:00 instead of 15:00) will be held one hour earlier than usual.)
Conference Call and Webcast Details
The conference call will
begin at 14:00 CET / 9:00 EDT on Tuesday October 30, 2018.
For Conference Call pre-registration, please use the following link:
http://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=6275474&linkSecurityString=28a182934
Alternatively interested parties may listen to the call by dialing: +1 760 294 1674 (U.S.), +44 203 059 5869 (UK), +49 69 566 037 000 (Germany).
The webcast will be accessible at:
https://corporate.qiagen.com/2018_Q3
A conference call replay will be available by using the following link:
https://services.choruscall.eu/links/qiagen181030.html
Contact: IR@qiagen.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of June 30, 2018, QIAGEN employed approximately 4,800 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.